SCHEMBL4428318

SCHEMBL4428318

CCNc1ccc(I)cc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 4/20 0.61
LMNA P02545 1/20 0.58
ALDH1A1 P00352 5/20 0.51
MAPT P10636 5/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
HTT P42858 1/20 0.48
GAA P10253 1/20 0.47
KAT2B Q92831 3/20 0.46
PKM P14618 2/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 1/20 0.44
CRHBP P24387 1/20 0.44
RAB9A P51151 1/20 0.44
CRHR2 Q13324 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30263650 1.00 HCAR3 (0.61) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL30169708 0.81 HCAR3 (0.63) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL6250970 0.81 KAT2B (0.66) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL5981763 0.81 HCAR3 (0.63) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL14676341 0.81 HCAR3 (0.58) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL10182457 0.81 ALDH1A1 (0.62) HCAR3LMNAALDH1A1MAPTKAT2B
SCHEMBL5149985 0.80 ALDH1A1 (0.67) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL594213 0.80 HCAR3 (0.61) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL10891363 0.80 HCAR3 (0.66) HCAR3LMNAALDH1A1MAPTL3MBTL1
SCHEMBL2336839 0.80 HCAR3 (0.61) HCAR3LMNAALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
CN-116096707-A Inhibitors of fibroblast growth factor receptor kinase 金耐特生物制药公司 2023-05-09 CN disclosed
EP-4161657-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES Kinnate Biopharma Inc. (US) 2023-04-12 EP disclosed
EP-2125856-A2 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING Lasergen, Inc. (US) 2009-12-02 EP disclosed
WO-2008070749-A2 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 HCAR3 2136/4885LMNA 2611/4885ALDH1A1 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.